Ctrl K
Last 23 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -18.07 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 6.72 | 4.15 | 3.16 | 1.68 | 0.77 | 0.45 | 0.43 | 0.55 | 1.56 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | +818.9% | +641.3% | +205.3% | -50.5% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -32.1% | -7.0% | -8.9% | -10.4% | -7.1% | -4.6% | -10.3% | -3.9% | -4.0% | -33.4% | -1.6% | -3.4% | -3.6% | -4.6% | -18.2% | -5.9% | -7.0% | -9.8% | -8.2% | -6.1% | -6.9% |
| — | -52.3% | +13.3% | -165.6% | -76.2% | +86.3% | -546.6% | -16.7% | -13.0% | -633.8% | +91.3% | +43.2% | +49.0% | +53.6% | -121.6% | +3.8% | -1.4% | +14.7% | +84.3% | +91.1% | — | |
| ROA | -31.1% | -6.8% | -8.6% | -10.0% | -6.9% | -4.4% | -9.9% | -3.8% | -4.0% | -32.7% | -1.5% | -3.3% | -3.5% | -4.4% | -17.3% | -5.6% | -6.7% | -9.3% | -7.9% | -5.9% | -6.6% |
| — | -53.6% | +13.8% | -161.2% | -73.3% | +86.5% | -544.1% | -17.4% | -14.5% | -647.4% | +91.1% | +42.0% | +47.9% | +53.1% | -120.4% | +5.1% | -0.3% | +13.6% | +83.4% | +90.2% | — | |
| ROIC | -40.6% | -6.8% | -8.6% | -10.4% | -7.1% | -4.9% | -11.9% | -8.3% | -24.5% | -10375.2% | -27.5% | -11.4% | -5.3% | -5.9% | -20.8% | -7.8% | -6.3% | -8.8% | -8.1% | -6.9% | -12.1% |
| — | -40.3% | +27.8% | -26.3% | +71.1% | +100.0% | +56.6% | +27.1% | -358.9% | -175963.0% | -31.8% | -46.2% | +14.9% | +32.8% | -158.5% | -13.2% | +48.2% | +97.2% | +97.8% | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | — | — |
| — | +59.4% | +32.0% | +34.2% | +1136.6% | +664.4% | +15.9% | -22.6% | -93.7% | -91.3% | -64.0% | -13.0% | -1.6% | +6.4% | +8.6% | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 15.16 | 31.45 | 27.86 | 15.16 | 18.38 | 14.08 | 14.25 | 31.41 | 57.73 | 60.41 | 37.02 | 38.92 | 38.76 | 31.58 | 24.45 | 22.04 | 21.21 | 17.48 | 19.33 | 24.58 | 28.38 |
| — | +123.3% | +95.5% | -51.7% | -68.2% | -76.7% | -61.5% | -19.3% | +49.0% | +91.3% | +51.4% | +76.6% | +82.8% | +80.7% | +26.5% | -10.3% | -25.3% | -4.7% | +49.7% | +242.3% | — | |
| Quick Ratio | 15.16 | 31.45 | 27.86 | 15.16 | 18.38 | 14.08 | 14.25 | 31.41 | 57.73 | 60.41 | 37.02 | 38.92 | 38.76 | 31.58 | 24.45 | 22.04 | 21.21 | 17.48 | 19.33 | 24.58 | 28.38 |
| — | +123.3% | +95.5% | -51.7% | -68.2% | -76.7% | -61.5% | -19.3% | +49.0% | +91.3% | +51.4% | +76.6% | +82.8% | +80.7% | +26.5% | -10.3% | -25.3% | -4.7% | +49.7% | +242.3% | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 23 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CLYM stock.
Climb Bio, Inc.'s current P/E is -18.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Climb Bio, Inc.'s business trajectory between earnings reports.